Holding Out Hope for HF Shunts, Even After an FDA Panel’s Doubts

Why It Matters

The decision underscores the high evidentiary bar for device approvals in heart failure, signaling that only rigorously proven, phenotype‑targeted therapies will gain market access. Successful refinement could add a novel, non‑pharmacologic option for high‑risk HFrEF and HFpEF patients.

Key Takeaways

• FDA panel rejected V‑Wave shunt due to neutral primary endpoint
• Subgroup analysis showed benefit in HFrEF patients only
• Patient selection and hemodynamics critical for shunt success
• Multiple shunt designs in development, some without permanent implants
• Long‑term safety data on right‑heart effects remain limited

Pulse Analysis

Interatrial shunting has re‑emerged as a potential bridge for patients with advanced heart failure, yet the recent FDA advisory panel vote highlights the regulatory challenges of translating early promise into approved therapy. The RELIEVE‑HF trial, which enrolled 508 participants, failed to meet its composite primary endpoint, prompting the panel to dismiss the V‑Wave device despite a statistically significant reduction in adverse events among the HFrEF subgroup. This outcome reflects the agency’s insistence that neutral primary results cannot be overridden by post‑hoc analyses, reinforcing the need for robust, pre‑specified efficacy signals.

The heterogeneity of heart‑failure phenotypes complicates device development. HFrEF patients with persistent NYHA class III symptoms despite optimal GDMT may derive the most benefit, as they exhibit elevated left‑atrial pressures that shunts can unload. Conversely, HFpEF and HFmrEF cohorts require nuanced hemodynamic profiling—exercise‑induced pressure spikes, absence of pulmonary vascular disease, and specific congestion phenotypes—to identify “responders.” Ongoing trials such as REDUCE LAP‑HF II, ALT‑FLOW II, and ALLAY‑HF are testing refined inclusion criteria and alternative shunt architectures, including pressure‑responsive and septum‑sparing designs, to improve signal detection.

Safety remains a pivotal concern, particularly the long‑term impact of chronic left‑to‑right flow on right‑ventricular remodeling. Short‑term data suggest acceptable procedural risk and stable RV function up to three years, but five‑ to ten‑year outcomes are still unknown. Emerging second‑generation devices with adaptive lumen control aim to mitigate right‑heart overload, while parallel advances in obesity‑targeted therapies may reduce the need for shunting in certain HFpEF patients. If forthcoming studies confirm durable efficacy and safety, interatrial shunts could become a valuable adjunct to pharmacologic regimens, expanding therapeutic options for a growing heart‑failure population projected to exceed 8 million by 2030.